VBWG
Data alert

New ACC/AHA Guidelines: Expanding the Role of Angiotensin Receptor Blockade in Heart Failure with LV Dysfunction

The 2005 ACC/AHA updated guidelines for the treatment of chronic HF and LV dysfunction in adults include an expanded role for ARBs as alternative therapy to ACEIs in selected patients and as added neurohormonal therapy in patients with persistent symptoms who are receiving optimal treatment. These new recommendations provide a safe and effective treatment option to reduce mortality and morbidity and slow progression of the disease. To date, candesartan and valsartan are the only two ARBs with demonstrated safety and efficacy in this patient population.




Data_Alert.pdf (0.7MB)Data_Alert.pdf (0.7MB)

Heart failure: The national burden

Download VBWG06_DataAlert_HF.ppt (10 slides - 0.2MB)

Heart failure: The national burden ACC/AHA: Heart failure stages A and B ACC/AHA: Heart failure stages C and D CHARM: HF patients with LV dysfunction VALIANT: Study design VALIANT: Primary outcome—Death from any cause ACC/AHA recommendations: ARBs in patients with LV dysfunction CHARM-Added: Effects of adding candesartan to -blocker and ACEI HF with LV dysfunction: Patients, efficacy, and dosing considerations CHARM: Prevention of diabetes with candesartan


ACCACEIsAHAangiotensinARBsblockadeDysfunctionexpandedexpandingHFLVneurohormonal

Related at vwbg.org

HOPE-TOO: Extended use of ACEI reduces CV risk and new diabetes, independent of baseline risk

Results from large clinical trials provide evidence that angiotensin-converting enzyme inhibitors (ACEIs) are effective in the treatment of cardiovascular (CV) disease.

The CHARM program: Enhancement of RAAS manipulation in heart failure

Clinical trials have demonstrated the benefits of angiotensin-converting enzyme (ACE) inhibitors 1 and ß-blockers 2-4 in patients with chronic heart failure (HF) and reduced left ventricular ejection fraction (LVEF).

MERIT-HF: Benefits of ß-blockade in women with heart failure and reduced left ventricular function

Under-representation of women in heart failure (HF) clinical trials has created uncertainty about the efficacy of various treatment strategies in women.
More related